Post by Symeres

The DMPK community is gathering in Basel this week for ISSX's Annual Meeting. As drug modalities diversify and ADME questions get more complex, the field is grappling with a shift: it's no longer just about what to measure, but how to interpret what it means for human risk. That tension is where a lot of programs get stuck. And it's exactly the kind of challenge our team spends time thinking about. Two of our ADME-Tox experts will be there: Dr Miia Kovalainen, Head of Business Development, focuses on ADME-Tox strategy and regulatory in vitro DDI packages — the kind of work that bridges discovery insights with IND-ready documentation. Dr Laszlo Szilagyi, Director of Business Development, brings deep expertise and a systems-level view of how ADME fits into integrated CRO/CDMO programs. They're looking forward to exchanging ideas on emerging DMPK approaches, predictive modeling, and how better data integration is reshaping the way teams move from candidate selection to clinic. Attending ISSX and want to talk through an ADME-Tox challenge? Miia and Laszlo would be happy to connect in Basel. Schedule a meeting with our team here: https://brnw.ch/21x3Jb5